

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GLORY 国瑞

Glory Health Industry Limited

國瑞健康產業有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2329)

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Glory Health Industry Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Mr. Deng Zhidong (“**Mr. Deng**”) has been appointed as an independent non-executive director of the Company, and as the chairman of the Remuneration Committee and a member of each of the Audit Committee and the Nomination Committee of the Company, with effect from January 29, 2024.

The biographical details of Mr. Deng are set out as below:

Mr. Deng Zhidong, aged 56, possesses certificates such as PRC certified public valuer, PRC certified real estate appraiser and the qualification for practicing in the Chinese securities industry. Mr. Deng worked at companies such as Zhong Fa International Asset Valuation Company Limited, CBRE Limited and Beijing Shanshui Wenyuan Real Estate Company. Mr. Deng has extensive experience in asset valuation, property valuation and consulting and other aspects.

Mr. Deng will enter into a director’s service agreement with the Company for a term of three years commencing from January 29, 2024, which may be terminated by both parties in accordance with the terms of the agreement. Mr. Deng shall hold office until the next following annual general meeting and will be subject to retirement by rotation and re-election at annual general meeting of the Company in accordance with the articles of association of the Company. Pursuant to the service agreement, Mr. Deng will be entitled to a Director’s emolument of HKD330,000 per annum which was determined by the Board with reference to Mr. Deng’s experience, knowledge, qualification, duties and responsibilities and the prevailing market conditions.

Save as disclosed above, as at the date of this announcement, Mr. Deng (i) has not held any other positions with any members of the Group; (ii) is not related to any director, senior management, substantial shareholder or controlling shareholder of the Company or other members of the Group; (iii) is not interested in the shares of the Company as defined in Part XV of the Securities and Futures Ordinance; and (iv) has not held any other directorships in any other listed public companies in the last three years.

Save as disclosed above, Mr. Deng has confirmed that there is no other information required to be brought to the attention of the shareholders of the Company and the Company or to be disclosed pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited in relation to his appointment as an independent non-executive director of the Company.

Upon the appointment of Mr. Deng, the Company is still not in compliance with the requirements set out in Rules 3.10(1), 3.10A and 3.21 of the Listing Rules. The Company will use its best efforts to identify suitable candidate to act as an independent non-executive director and the member of the Audit Committee if practicable, to meet the requirements set out in Rules 3.10(1), 3.10A and 3.21 of the Listing Rules, and will make further announcement(s) as and when appropriate.

The Board would like to take this opportunity to express its warmest welcome to Mr. Deng in joining the Board.

By Order of the Board
Glory Health Industry Limited
Zhang Zhangsun
Chairman

Beijing, the PRC, January 29, 2024

As at the date of this announcement, the board of directors of the Company comprises Mr. Zhang Zhangsun, Ms. Ruan Wenjuan, Mr. Yang Huabin, Mr. Feng Yang and Mr. Zhao Yuhong as executive directors and Ms. Chen Jinrong and Mr. Deng Zhidong as independent non-executive directors.